Latest Clinical trials biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

El Institut Guttmann lidera el primer ensayo clínico para reducir las secuelas de la cirugía de tumores cerebrales modificando la actividad del cerebro antes de la operación

by Institut Guttmann

7 months ago
PREHABILITA, neuroestimulación, Institut Guttmann

Se trata del primer ensayo clínico en el mundo para evaluar el uso de estos métodos no invasivos antes de una intervención de tumor cerebral. Su aplicación permitiría reducir el número de cirug�...

FDA Allows Oncoheroes to Begin Two Pediatric Oncology Clinical Trials

by Oncoheroes Biosciences

7 months ago
volasertib, dovitinib, Oncoheroes

Oncoheroes Biosciences, Inc. (“Oncoheroes”) announced today that the U.S. Food and Drug Administration (FDA) has allowed the Boston-based biotech to proceed with the investigation of two potential...

Research led in Bellvitge will allow progress in the fight against bacteremia

by IDIBELL - Institut d’Investigació Biomèdica de Bellvitge

7 months ago
methicillin-sensitive Staphylococcus aureus (MSSA)., fosfomycin and cloxacillin

It has been published the results of a clinical trial evaluating the efficacy of combined treatment with fosfomycin and cloxacillin in patients with bacteremia due to methicillin-sensitive Staphylococ...

Against breast cancer

by Universitat Politècnica de València

7 months ago
tanshinone IIA, carnasol

A study led by the ITQ (UPV-CSIC) demonstrates the anti-tumour properties of analogues of tanshinone IIA and carnosol

The Mediterranean per diem expenses could lose between 12% and 24% of its protection if moderate wine consumption were eliminated.

by Universidad de Navarra

7 months ago
Mediterranean per diem, wine

One of the highlights of his presentation was the estimate that the Mediterranean per diem expenses could lose between 12% and 24% of its protection if moderate wine consumption, defined as up to 1 gl...

OneChain Immunotherapeutics achieves FDA Orphan Drug designation for OC-1

by Parc Científic de Barcelona

7 months ago
OneChain Immunotherapeutics, acute lymphoblastic leukemia (ALL), OC-1

Spanish biotech OneChain Immunotherapeutics (OCI), has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA)to OC-1, a CAR T therapy against for the treatment of acute lymp...

ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

by Oryzon Genomics

7 months ago
borderline personality disorder (BPD), Phase IIb PORTICO, vafidemstat

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company presented an ...

Results on the preclinical efficacy of uric acid in ischaemic stroke published

by Fundació Clínic per a la Recerca Biomèdica

7 months ago
ischaemic stroke, uric acid, Ox-01, FreeOx Biotech, Stroke Preclinical Assessment Network (SPAN)

The journal Science Translational Medicine has published the results of a preclinical study carried out on rodents that shows the efficacy of uric acid in improving the prognosis of ischaemic stroke. ...

Identificadas nuevas dianas terapéuticas para el tratamiento de cáncer de pulmón

by Professional Newco

7 months ago
proteínas SOS, mutaciones en KRAS, adenocarcinoma de pulmón

El grupo de investigación dirigido por el profesor Eugenio Santos, investigador principal del Centro de Investigación del Cáncer (Universidad de Salamanca-CSIC) y de CIBERONC (Instituto de Salud Ca...

Asabys’ portfolio company Agomab Raises $100 Million Series C from Fidelity, EQT Life Sciences, Canaan and KKR

by Asabys Partners

7 months ago
AGMB-129, Fibrostenosing Crohn’s Disease (FSCD), Agomab, Idiopathic Pulmonary Fibrosis, Asabys

Agomab Therapeutics NV ('Agomab') today announced the closing of a $100 million Series C round of financing to support the Phase 2a clinical trial evaluating Agomab's lead drug candidate, AGMB-129, a ...

VHIO desarrolla una herramienta que ayudará a predecir qué pacientes podrían beneficiarse de la inmunoterapia

by Vall d’Hebron

7 months ago
VIGex, inmunoterapia

VIGex es una firma de expresión génica que clasifica los tumores sólidos en tres categorías según el estado de activación de los genes de respuesta inmunológica adaptativa: Caliente, Intermedio...

AM-Pharma announces positive clinical data from phase 1b study evaluating ilofotase alfa in hypophosphatasia

by Ysios Capital

7 months ago
hypophosphatasia (HPP), Ilofotase alfa, AM-Pharma B.V.

AM-Pharma B.V. today announced positive clinical results from the Phase 1b study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as potential enzyme replacemen...